药食两用纳豆激酶的研究进展

本文从血栓栓塞疾病的形成机制为依据,综述了纳豆激酶的药理作用。介绍了国内外产纤溶酶菌株的筛选方法,纳豆激酶的分离、纯化常用技术,纳豆激酶的生理生化特性、活性测定方法。并说明了影响纳豆激酶稳定的4个因素,和增加纳豆激酶产量的有效方法。通过药食两用纳豆激酶的研究进展,希望对纳豆激酶的研究提供理论基础。     

组氨酸激酶(YycG)在筛选肺炎链球菌抑制剂中的应用

为了获得具有体外活性的肺炎链球菌组氨酸激酶YycG并利用其筛选寻找新的抑制剂。原核表达组氨酸激酶YycG的激酶功能域,经SDS-PAGE,Western blot鉴定及镍层析柱纯化后,采用激酶试剂盒检测其激酶活性;利用对其激酶活性的抑制作用从105种候选化合物中筛选有效的抑制剂,并通过实验验证抑制剂的抗菌作用。原核表达得到约35 kDa的目的蛋白激酶域片段YycG′,其纯度达 95 %,并具有体外水解ATP的激酶活性;利用其活性筛选得到数种不同抑制效果的小分子化合物,且体外验证具有较好的抑菌效果。通过肺炎链球菌组氨酸激酶YycG活性筛选找到的小分子抑制剂可为进一步研发与该菌相关的药物或消毒剂提供基础。     

XA21和PI-D2激酶蛋白质在酿酒酵母中的表达及其自我磷酸化研究

白叶枯病和稻瘟病是最主要的水稻病害。Xa21是水稻白叶枯病抗性基因,Pi-d2是稻瘟病抗性基因,二者都编码类受体激酶蛋白质。在前期研究中,曾系统地研究了细菌中表达XA21激酶蛋白质的生化活性。在此实验中利用真核表达系统酿酒酵母对Xa21和Pi-d2编码的蛋白激酶进行了表达、纯化及自我磷酸化活性分析,为进一步的生化分析、蛋白质-蛋白质相互作用研究、底物筛选等奠定了基础。     

3-磷酸肌醇依赖性蛋白激酶1结构和功能

PDK1可调节AGC激酶家族中一些重要蛋白激酶。这些激酶包括蛋白激酶B（PKB／Akt）、p70核小体S6激酶（p70 ribosomal S6 kinase,S6K）、血清和糖皮质激素诱导激酶（SGK）和蛋白激酶C（PKC）等,它们在细胞代谢、生长、增殖和存活等生理过程中具有重要作用。因此,了解PDK1生物学特性可能对其调节的AGC激酶持续活化的癌症治疗具有一定推动作用。本文对PDK1的结构、遗传和生化特点进行了综述。     

玉米根尖细胞液泡膜结合的蛋白激酶的存在及其性质

为了解液泡膜蛋白在植物细胞信号途径中的功能 ,用新型的非放射性同位素方法从玉米根细胞的高纯度液泡膜上鉴定出一种膜内在的蛋白激酶。这种蛋白激酶具有Ca2 依赖、CaM和磷脂酰丝氨酸不依赖等特性 ,与已在多种植物中报道的含有类似钙调素结构域的蛋白激酶CDPK相似。离体实验表明其活性的最适pH值为 6 .5 ,最适Ca2 浓度为 1 0 μmol/L。从最适pH值和去污剂的影响可以推测出其活性位点朝向胞质一侧。Zn2 对其活性没有明显的抑制作用 ,说明该激酶缺少某些哺乳动物的蛋白激酶常含有的锌指结构。当液泡膜蛋白在Ca2 和ATP存在的条件下被预磷酸化后 ,液泡膜H _ATPase的ATP水解和质子转运过程均被激活。激活的活性可以被碱性磷酸酶逆转。以上结果说明玉米根尖细胞的液泡膜中存在一种可能是CDPK的蛋白激酶。由它造成的Ca2 依赖的磷酸化作用激活了液泡膜H _ATPase的活性。这些结果将有助于深入研究CDPK在植物细胞信号转导中的功能。     

喉癌中差异表达的蛋白激酶及其抑制剂的生物信息学筛选

目的：筛选喉癌中差异表达的激酶基因以及调控这些差异表达激酶的激酶抑制剂,为喉癌的分子治疗提供新的靶点。方法： 利用PubMed 数据库和SAM 软件筛选喉癌中差异表达的激酶基因。体外培养人喉癌Hep-2和FaDu 细胞。实时定量聚合酶链反 应（Real-time PCR）检测目的激酶在喉癌细胞系中的表达,以验证全基因表达谱结果的准确性。利用KEGG数据库获得激酶调控 的通路。文献挖掘和人工筛选获得差异表达激酶的激酶抑制剂。结果：①在喉癌基因组表达谱中,共筛选出差异表达基因207个, P<0.05,其中激酶基因4 个,分别为CDC42、CDK7、SLK 和TXK。②Real-time PCR 结果显示在人喉癌Hep-2 和FaDu 细胞中这四 个差异基因也出现差异表达,P<0.05,证明全基因组的结果准确。③通路分析的结果显示4 个差异激酶共调控25 个通路。④文献 挖掘和人工筛选的结果显示共有10 个激酶抑制剂调控CDC42,7 个激酶抑制剂调控CDK7,1 个激酶抑制剂调控SLK,2 个激酶 抑制剂调控TXK。并且再次文献挖掘的结果显示在这20 个激酶抑制剂中,有9 个在癌症方面的研究较少,文献<10 篇。结论： 喉癌中共有四个激酶CDC42、CDK7、SLK 和TXK发生差异表达,并发挥促癌作用。它们的激酶抑制剂可能有潜在的抗癌作用, 为喉癌的分子治疗提供新的切入点。     

一种具有纤溶活性的枯草杆菌蛋白激酶的研究──Ⅰ高产酶菌株的筛选与鉴定

本文主要阐述了一种具有纤溶活性的枯草杆菌（Ｂａｃｉｌｌｕｓｓｕｂｔｉｌｉｓ）蛋白激酶产生菌株的筛选与鉴定的研究结果。作者从初筛的１２株Ｂａｃｉｌｌｕｓｓｕｂｌｉｌｉｓ菌中,通过对固体发酵和液体发酵所产生的枯草杆菌蛋白激酶,用琼脂糖－纤维蛋白平板法测其活性,经比较不同菌株的活性,筛选出两株高产酶菌株：Ｂ．ｓｕｂｔｉｌｉｓＨＷ—１２和Ｂ．ｓｕｂｔｉｌｉｓＨＷ—３。同时对菌体和菌落形态特点、生理生化反应进行了鉴定,认为Ｂ．ＳｕｂｔｉｌｉｓＨＷ－１２菌株可用来做为发酵生产该酶的菌种。     

蛋白激酶Cδ的克隆表达纯化及其在药物先导化合物筛选中的初步应用

蛋白激酶C家族是一类磷脂酰丝氨酸依赖丝氨酸 苏氨酸蛋白激酶。PKCδ(蛋白激酶Cδ)是蛋白激酶C家族成员。PKCδ的异常激活将会导致糖尿病和多种癌症的发生 ,因此 ,PKCδ的特异性抑制剂能成为治疗这些疾病的潜在药物 ,如能以PKCδ为分子靶点来筛选特异性抑制剂 ,就可以建立癌症及糖尿病的药物先导化合物筛选模型。通过RT-PCR的方法 ,克隆了鼠源的PKCδ,并构建了哺乳动物细胞表达载体 ,获得了可稳定表达PKCδ的COS1细胞株。通过亲和吸附的方法获得了较为纯净的PKCδ ,并对酶学活性作了进一步的分析 ,建立了以PKCδ为靶点的药物先导化合物筛选模型。     

GST-pull down方法鉴定Src激酶与PSD-95的直接结合

脚手架蛋白PSD-95通过募集多种蛋白质在包括缺血性脑中风在内的多种神经系统疾病中具有重要的作用。Src蛋白激酶家族是膜相关非受体酪氨酸蛋白激酶中最大的家族,该家族激酶含有与突触后致密蛋白PSD-95相结合的结构域。Src激酶是其家族中主要成员之一,在脑组织中表达丰富。脑缺血/再灌注引起缺血敏感区Src激酶活性的显著增强。之前的研究表明,Src激酶参与调节PSD-95酪氨酸磷酸化。本实验主要通过GST-pull down实验体外鉴定Src与PSD-95之间的直接结合。     

玉米根尖细胞液泡膜结合的蛋白激酶的存在及其性质

为了解液泡膜蛋白在植物细胞信号途径中的功能,用新型的非放射性同位素方法从玉米根细胞的高纯度液泡膜上鉴定出一种膜内在的蛋白激酶.这种蛋白激酶具有Ca2+依赖、CaM和磷脂酰丝氨酸不依赖等特性,与已在多种植物中报道的含有类似钙调素结构域的蛋白激酶CDPK相似.离体实验表明其活性的最适pH值为6.5,最适Ca2+浓度为10 μmol/L.从最适pH值和去污剂的影响可以推测出其活性位点朝向胞质一侧.Zn2+对其活性没有明显的抑制作用,说明该激酶缺少某些哺乳动物的蛋白激酶常含有的锌指结构.当液泡膜蛋白在Ca2+和ATP存在的条件下被预磷酸化后,液泡膜H+-ATPase的ATP水解和质子转运过程均被激活.激活的活性可以被碱性磷酸酶逆转.以上结果说明玉米根尖细胞的液泡膜中存在一种可能是CDPK的蛋白激酶.由它造成的Ca2+依赖的磷酸化作用激活了液泡膜H+-ATPase的活性.这些结果将有助于深入研究CDPK在植物细胞信号转导中的功能.     

Quantitative methods for the analysis of protein phosphorylation in drug development

Most signal transduction and cell signaling pathways are mediated by protein kinases. Protein kinases have emerged as important cellular regulatory proteins in many aspects of neoplasia. Protein kinase inhibitors offer the opportunity to target diseases such as cancer with chemotherapeutic agents specific for the causative molecular defect. In order to identify possible targets and assess kinase inhibitors, quantitative methods for analyzing protein phosphorylation have been developed. This review examines some of the current formats used for quantifying kinase function for drug development.     

蛋白激酶组在玉米叶片ABA和H202诱导抗氧化防护中的作用

蛋白磷酸化在植物细胞脱落酸（ABA）介导的信号转导中起重要作用。然而,很多参与ABA信号途径的蛋白元件仍不清楚。使用改进的体外激酶试验方法的研究结果表明,在玉米叶片中,ABA和H2O2能够快速活化蛋白激酶总活性和ca^2＋依赖型蛋白激酶总活性;ABA诱导的蛋白激酶总活性增加可以被活性氧的抑制剂和清除剂抑制,蛋白激酶抑制剂不仅可以降低ABA和H2O2诱导的激酶活性增加,而且也可以弱化它们对抗氧化防护酶活性的诱导作用;ABA和H2O2引发的蛋白磷酸化作用显著居先于它们诱导的抗氧化防护作用。使用凝胶激酶试验方法进行研究发现,一组分子量分别为66kDa,52kDa,49kDa和35kDa的蛋白激酶可能介导了ABA和H2O2诱导的抗氧化防护反应,并且66kDa和49kDa的蛋白激酶可能在ROS的下游起作用,而52kDa和35kDa的蛋白激酶可能在ABA和ROS的下游起作用。     

Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F

The Janus kinase 2 mutant V617F occurs with high frequency in myeloproliferative neoplasms. Further mutations affecting the Janus kinase family have been discovered mostly in leukaemias and in myeloproliferative neoplasms. Owing to their involvement in neoplasia, inflammatory diseases and in the immune response, Janus kinases are promising targets for kinase inhibitor therapy in these disease settings. Various quantitative assays including two newly developed screening assays were used to characterize the function of different small‐molecule compounds in cells expressing Jak2V617F. A detailed comparative analysis of different Janus kinase inhibitors in our quantitative assays and the subsequent characterization of additional activities demonstrated for the first time that the most potent Jak2 inhibitor in our study, CEP701, also targets Aurora kinases. CEP701 shows a unique combination of both activities which is not found in other compounds also targeting Jak2. Furthermore, colony forming cell assays showed that Janus kinase 2 inhibitors preferentially suppressed the growth of erythroid colonies, whereas inhibitors of Aurora kinases preferentially blocked myeloid colony growth. CEP701 demonstrated a combined suppression of both colony types. Moreover, we show that combined application of a Janus and an Aurora kinase inhibitor recapitulated the effect observed for CEP701 but might allow for more flexibility in combining both activities in clinical settings, e.g. in the treatment of myeloproliferative neoplasms. The newly developed screening assays are high throughput compatible and allow an easy detection of new compounds with Janus kinase 2 inhibitory activity.     

Development of a high-throughput screening method for LIM kinase 1 using a luciferase-based assay of ATP consumption

Kinases are attractive drug targets because of the central roles they play in signal transduction pathways and human diseases. Their well-formed adenosine triphosphate (ATP)-binding pockets make ideal targets for small-molecule inhibitors. For drug discovery purposes, many peptide-based kinase assays have been developed that measure substrate phosphorylation using fluorescence-based readouts. However, for some kinases these assays may not be appropriate. In the case of the LIM kinases (LIMK), an inability to phosphorylate peptide substrates resulted in previous high-throughput screens (HTS) using radioactive labeling of recombinant cofilin protein as the readout. We describe the development of an HTS-compatible assay that measures relative ATP levels using luciferase-generated luminescence as a function of LIMK activity. The assay was inexpensive to perform, and proof-of-principle screening of kinase inhibitors demonstrated that compound potency against LIMK could be determined; ultimately, the assay was used for successful prosecution of automated HTS. Following HTS, the secondary assay format was changed to obtain more accurate measures of potency and mechanism of action using more complex (and expensive) assays. The luciferase assay nonetheless provides an inexpensive and reliable primary assay for HTS that allowed for the identification of LIMK inhibitors to initiate discovery programs for the eventual treatment of human diseases.     

Casein kinase activity in etiolated Cucumis sativus cotyledons

Two calcium- and light-dependent protein kinases have been reported in etiolated Cucumis sativus cotyledons (Vidal et al. 2007). In the present work, we studied casein kinase (CK) activity in etiolated cucumber cotyledons of in-gel and in vitro kinase assays, using specific CK inhibitors, and ATP and GTP as phosphate donors. Two proteins with CK activity were detected in both casein gels and autophosphorylation assays. One of them, with a molecular mass of approximately 36 kDa, showed biochemical CK1 characteristics: it was inhibited by specific CK1 inhibitors and only used ATP as phosphate donor. The second, with a molecular mass of approximately 38 kDa, had CK2 characteristics; it used both ATP and GTP as phosphate donors, was inhibited by all specific CK2 inhibitors, and was recognized by a polyclonal antibody directed against the α catalytic subunit of a CK2 from tobacco. The kinase activity of the CK2 detected in etiolated cucumber cotyledons showed circadian rhythmicity in both in vitro and in-gel casein phosphorylation and in autophosphorylation assays. Thus, our results suggest that the CK2 of approximately 38 kDa could be related to the circadian oscillator of C. sativus cotyledons.     

Three mechanistically distinct kinase assays compared: Measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors

Numerous assay methods have been developed to identify small-molecule effectors of protein kinases, but no single method can be applied to all isolated kinases. The authors developed a set of 3 high-throughput screening (HTS)-compatible biochemical assays that can measure 3 mechanistically distinct properties of a kinase active site, with the goal that at least 1 of the 3 would be applicable to any kinase selected as a target for drug discovery efforts. Two assays measure catalytically active enzyme: A dissociation-enhanced lanthanide fluoroimmuno assay (DELFIA) uses an antibody to quantitate the generation of phosphorylated substrate; a second assay uses luciferase to measure the consumption of adenosine triphosphate (ATP) during either phosphoryl-transfer to a peptide substrate or to water (intrinsic ATPase activity). A third assay, which is not dependent on a catalytically active enzyme, measures the competition for binding to kinase between an inhibitor and a fluorescent ATP binding site probe. To evaluate the suitability of these assays for drug discovery, the authors compared their ability to identify inhibitors of a nonreceptor protein tyrosine kinase from the Tec family, interleukin-2-inducible T cell kinase (ITK). The 3 assays agreed on 57% of the combined confirmed hit set identified from screening a 10,208-compound library enriched with known kinase inhibitors and molecules that were structurally similar. Among the 3 assays, the one measuring intrinsic ATPase activity produced the largest number of unique hits, the fewest unique misses, and the most comprehensive hit set, missing only 2.7% of the confirmed inhibitors identified by the other 2 assays combined. Based on these data, all 3 assay formats are viable for screening and together provide greater options for assay design depending on the targeted kinase.     

A generic time-resolved fluorescence assay for serine/threonine kinase activity: application to Cdc7/Dbf4

The serine/threonine protein kinase family is a large and diverse group of enzymes that are involved in the regulation of multiple cellular pathways. Elevated kinase activity has been implicated in many diseases and frequently targeted for the development of pharmacological inhibitors. Therefore, non-radioactive antibody-based kinase assays that allow high throughput screening of compound libraries have been developed. However, they require a generation of antibodies against the phosphorylated form of a specific substrate. We report here a time-resolved fluorescence assay platform that utilizes a commercially-available generic anti-phospho-threonine antibody and permits assaying kinases that are able to phosporylate threonin residues on protein substrates. Using this approach, we developed an assay for Cdc7/Dbf4 kinase activity, determined the K(m) for ATP, and identified rottlerin as a non-ATP competitive inhibitor of this enzyme.     

Production of active recombinant mitogen-activated protein kinases through transient transfection of 293T cells

Mitogen-activated protein (MAP) kinases are a family of serine/threonine protein kinases that play an important role in a myriad of cellular processes, including cell proliferation, differentiation, and apoptosis. Abnormal activation of MAP kinases has been shown to participate in a variety of human diseases which include cancer, septic shock, rheumatoid arthritis, diabetes, and cardiovascular diseases. Active MAP kinase enzymes are not only valuable for basic biomedical research but are also critical for the development of pharmacological inhibitors as therapeutic drugs in the treatment of relevant human diseases. MAP kinases produced in a bacterial system are poorly active due to a lack of proper phosphorylation at their characteristic threonine and tyrosine residues. To overcome these limitations, we have developed a mammalian expression system for high level expression and one-step purification of enzymatically MAP kinases. We cloned JNK1, p38, and p38-regulated MAP kinase-activated protein kinase-2 into the mammalian expression vector pEBG, and expressed these protein kinases as glutathione S-transferase fusion proteins in human embryonic kidney 293T cells through transient transfection. The protein kinases were activated in vivo through treating the transfected cells with sodium arsenite and affinity-purified using glutathione-Sepharose beads. The enzymatic activities of these protein kinases were demonstrated by Western blot analysis and in vitro kinase assays. Our results indicate that this system is an extremely powerful tool for generating valuable reagents, and could be very valuable for proteomic studies.     

Quantitative methods for the analysis of protein phosphorylation in drug development

Most signal transduction and cell signaling pathways are mediated by protein kinases. Protein kinases have emerged as important cellular regulatory proteins in many aspects of neoplasia. Protein kinase inhibitors offer the opportunity to target diseases such as cancer with chemotherapeutic agents specific for the causative molecular defect. In order to identify possible targets and assess kinase inhibitors, quantitative methods for analyzing protein phosphorylation have been developed. This review examines some of the current formats used for quantifying kinase function for drug development.     

Mammalian histidine kinases

Protein phosphorylation is one of the most ubiquitous and important types of post-translational modification for the regulation of cell function. The importance of two-component histidine kinases in bacteria, fungi and plants has long been recognised. In mammals, the regulatory roles of serine/threonine and tyrosine kinases have attracted most attention. However, the existence of histidine kinases in mammalian cells has been known for many years, although little is still understood about their biological roles by comparison with the hydroxyamino acid kinases. In addition, with the exception of NDP kinase, other mammalian histidine kinases remain to be identified and characterised. NDP kinase is a multifunctional enzyme that appears to act as a protein histidine kinase and as such, to regulate the activation of some G-proteins. Histone H4 histidine kinase activity has been shown to correlate with cellular proliferation and there is evidence that it is an oncodevelopmental marker in liver. This review mainly concentrates on describing recent research on these two types of histidine kinase. Developments in methods for the detection and assay of histidine kinases, including mass spectrometric methods for the detection of phosphohistidines in proteins and in-gel kinase assays for histone H4 histidine kinases, are described. Little is known about inhibitors of mammalian histidine kinases, although there is much interest in two-component histidine kinase inhibitors as potential antibiotics. The inhibition of a histone H4 histidine kinase by genistein is described and that of two-component histidine kinase inhibitors of structurally-related mammalian protein kinases. In addition, recent findings concerning mammalian protein histidine phosphatases are briefly described.